Researchers Map LDLR Gene Regulatory Elements
The study identifies noncoding DNA sequences that control cholesterol receptor expression, offering new insights for genomics.
Updated on Oct. 25, 2026 in Life Sciences
Researchers have mapped the functional noncoding landscape of the LDLR gene using a combination of CRISPR screening and reporter assays. This study, currently at the research stage, identifies the specific cis-regulatory elements that control the expression of the gene.
Why it matters
Understanding the noncoding regulatory elements at the LDLR locus is essential for deciphering how genetic variants influence cholesterol levels and cardiovascular risk. This work fills a significant gap in the functional genomics of a gene critical to human lipid metabolism.
The study employed saturation CRISPR nuclease, CRISPR activation, and CRISPR inhibition screening to interrogate the LDLR locus. Each method successfully discriminated control sequences to reveal distinct, overlapping regions that influence gene expression.
The players
LDLR Gene
A gene responsible for the production of the low-density lipoprotein receptor, a critical protein for clearing cholesterol from the bloodstream.
The details
The researchers applied a massively parallel reporter assay—a technique that measures the activity of thousands of DNA sequences simultaneously—to map the LDLR gene. By using CRISPR nuclease, activation, and inhibition screenings, the team systematically turned regulatory sequences on or off to observe changes in gene output. This approach allows scientists to pinpoint cis-regulatory elements, which are non-coding regions of DNA that regulate the transcription of neighboring genes, rather than coding for proteins themselves.
Timeline
October 2026: Publication of the functional genomics study.
The Tech Race
This research follows the precedent of the ENCODE project by providing a granular functional map of a specific, clinically relevant genomic locus. It advances the field beyond simple mapping toward understanding the functional logic of the noncoding genome.
This work is currently at the research stage and does not immediately change clinical testing or treatment for cholesterol management. It provides a foundation for future diagnostic tools that may eventually predict individual cardiovascular risk more accurately.
The takeaway
The research establishes a new baseline for understanding how the LDLR gene is regulated by noncoding DNA. Interested researchers should monitor follow-up studies that link these identified cis-regulatory elements to specific human lipid-related disease phenotypes.
Further reading
For broader trends in genetic research, see the latest developments in Life Sciences.
More information
View the complete biorxiv functional genomics research paper for technical methodology.
Source note: This article includes information reported by Biorxiv.
